Tsveta Milanova Sells 2,770 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Tsveta Milanova sold 2,770 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $92,905.80. Following the completion of the transaction, the insider now directly owns 26,122 shares of the company's stock, valued at approximately $876,131.88. The trade was a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock traded down $0.18 during trading hours on Friday, hitting $33.47. 489,988 shares of the company were exchanged, compared to its average volume of 651,989. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The business's 50-day simple moving average is $31.27 and its two-hundred day simple moving average is $32.11. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of 2.98 and a beta of 0.73.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. The firm had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. As a group, analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of large investors have recently bought and sold shares of AGIO. Venturi Wealth Management LLC bought a new position in Agios Pharmaceuticals in the fourth quarter worth about $33,000. GF Fund Management CO. LTD. bought a new position in Agios Pharmaceuticals in the fourth quarter worth about $39,000. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals in the first quarter worth about $40,000. CWM LLC lifted its holdings in Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 996 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its holdings in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after acquiring an additional 1,587 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Scotiabank reduced their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research report on Friday, May 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.60.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.